

4. Belsito, D., A. F. Fransway, J. F. Fowler et al., Allergic contact dermatitis to detergents: A multicenter study to assess prevalence, *J Am.Acad Dermatol*, 2002, 46, 200.
5. Brasch, J., J. Burgard, W. Sterry , Common pathogenetic pathways in allergic and irritant contact dermatitis, *J. Invest Dermatol*, 1992, 98, 166-170.
6. Brown, T., Strategies for prevention: occupational contact dermatitis, *Occup Med (Lond.)*, 2004,54, 7, 450-7.
7. Cohen, D.E., Contact dermatitis: A quarter century perspective, *J. Am. Acad. Dermatol.*, 2004,51,60-63.
8. Code-Salazar, L., M. Baz, D. Guimaraens et al., Contact dermatitis in hairdressers: Patch test results in 139 hairdressers (1980-1993), *Am J Contact Dermatitis*, 1995, 6, 19-23.
9. English, J. S., Current concepts of irritant contact dermatitis, *Occup. Environ. Med.*, 2004 , 61, 722-6, 674.
10. Fischer, A. A., A. Pelzic, N. B. Kanof, The persistence of allergic eczematous sensitivity and the cross-sensitivity pattern to paraphenyldiamine, *J. Invest. Dermatol.*, 30, 1958, 9-12.
11. Fischer, A.A., Nonoccupational dermatitis due "black" paraphenyldiamine rubber chemicals: Part 1, *Cutis*, 49, 1992, 163-164.
12. Gallo, R., G. Ghigliotti, E. Gozzani et al., Contact dermatitis from para-phenyldiamine used as a skin paint: A further case, *Contact Dermatitis*, 1990, 40, 57.
13. Horio, T., Allergic and photoallergic dermatitis from diphenylhydramin, *Arch. Dermatol.*, 112, 1976, 1124-1126.
14. Huygens, S., A. Goossens, An update on airborne contact dermatitis, *Contact Dermatitis*, 2001, 44, 1, 1-6.
15. Klein, A. D., O. G. Rodman, Allergic contact dermatitis to paraphenyldiamine in hair dye: Case report, *Military Medicine*, 1981, 146, 46-47.
16. Kutting, B., R. Brehler, H. Traupe, Allergic contact dermatitis in children: strategies of prevention and risk management, *Eur. J. Dermatol.*, 2004, 14, 2, 80-5.
17. Michael, T., B. Niggemann, A. Moers et al., Risk factors for latex allergy in patients with spina bifida, *Clin. Exp. Allergy*, 1996, 26, 934.
18. Nettis, E., M.C. Colanardi, A.L. Soccio, A. Ferrannini, A. Tursi, Occupational irritant and allergic contact dermatitis among healthcare workers, *Contact Dermatitis*, 2002, 46, 101 – 107.
19. Templet, J. T., S. Hall, D. V. Belsito, Etiology of hand dermatitis among patients referred for patch testing, *Dermatitis*, 2004, 15, 1, 25 – 32.
20. Wesley, N. O., H. I. Maibach, Decreasing allergic contact dermatitis frequency through dermatotoxicologic and epidemiologic based intervention, *Food Chem. Toxicol.*, 2003, 41, 6, 857 – 60.

Journal of IMAB - Annual Proceeding (Scientific Papers) 2006, book 3

OUR TRAIL IN TREATMENT AND PROPHYLAXIS OF COLD URTICARIA WITH DESLORATADINE

S. Racheva, P. Drumeva, F. Georgieva*
*Department of Dermatology and Venerology,
 Medical University Prof. Dr. Paraskev Stoyanov – Varna, Bulgaria
 Medical University and "St. Anna" Hospital- Varna,*

RESUME

Cold urticaria presents in quite a lot of cases (31%) with physical urticaria. Its effective treatment and prophylaxis are a problem that is solved by using H1 blockers.

Good alternative method nowadays is Desloratadine - Aerius, having maximal effect with minimal risk of adverse reactions.

Our study included 30 patients with different forms of cold urticaria: hereditary cold urticaria – 4 patients, acquired cold urticaria (contact and refractory) – 13 patients, symptomatic cold urticaria (coexisting with viral infections, medicaments, mycoses) - 8 patients, cold cholinergic urticaria – 5 patients.

All the patients were treated with Desloratadine 1 tablet daily till the end of the clinical features. Afterwards all the patients were prophylacted in the following two months with the same medicament.

The results were: the clinical features disappeared in

all the patients in the next 2 weeks; the prophylaxis with Desloratadine was effective in 80% of the treated patients. These allow us to make the conclusion that Desloratadine is a good choice in the treatment and prophylaxis of cold urticaria.

INTRODUCTION

Cold urticaria presents in quite a lot of cases (31%) with physical urticaria. It can be with acute duration (some weeks) or with long duration (years). There are described cases of cold urticaria associated with vasculitis (5), viral infections (2), and in 2-3% with cryoglobulinemia (15, 18). In most cases it is acquired, determined by IgE (18). Its effective treatment and prophylaxis are a problem that is solved usually by using H1 blockers. They are an effective choice in the treatment of cold urticaria (20, 10, 25). Good results are mentioned by using cyproheptadine as monotherapy (22, 18, 24, 19, 26) or in combination with chlorpheniramin (23)

or ketotifen (17, 21). Very good inhibition of cold urticaria reaction is reached by using of cetirizine (1,11) or new generation of H1 blockers – mizolastine (4), and acrivistine (16), as well as combined therapy with H1 and H2 blockers (3,9). Taking in mind the higher levels of leucotriens in the serum of patients suffered from cold urticaria (13) there are an effective tries of treating with antagonists of leucotrien-receptors: monilukast (8), Zafirlukast (1). Doubted results are achieved in the treating of cold urticaria with cyclosporine (14).

There is a tendency to use new H1 blockers. A good outlook in this attitude is the medicine Aeries (Desloratadine – Schering Ploght) – high effective in treatment and prophylaxis and low risk of side effects.

Purpose of investigation

The study evaluates the cure effects and the efficacy of Desloratadine for the treatment and prophylaxis of different type of cold urticaria.

MATERIAL AND METHODS

Our study included 30 patients with different forms of cold urticaria: hereditary cold urticaria – 4 patients, acquired cold urticaria (contact and refractory) – 13 patients, symptomatic cold urticaria (coexisting with viral infections, medicaments, mycoses) - 8 patients, cold cholinergic urticaria – 5 patients.


All the patients were treated with Aeries (Desloratadine) 1 tablet daily till the end of the clinical features. The patients were examined four times: after the first, second, third and fourth week. Afterwards all the patients were prophylacted in the following two months with the same medicament and made a visit after the first and second month.

RESULTS

The cure effect was measured by two indexes: the number of still existing skin lesions and itching (absent, mild or moderate).

In all 30 patients after the second week of treatment there was a good therapeutic result (**diagram 1**):


Diagram 1. Therapeutic results in 30 patients with cold urticaria - index-number of wheals



80% were without wheals, 10% with one or two wheals and 10% with moderate number of wheals. After the third week the similar results were observed and the number of patients with moderate number of wheals lowers to 5%. At the end of the ford week there was an excellent effect in 90% and only 10% were with one or two wheals.

The results measured for criteria pruritus were even better (**diagram 2**):


Diagram 2. Therapeutic results in 30 patients with cold urticaria –criteria-pruritus



after the second week only 10% were with mild itch and 5% with moderate. At the end of the ford week 95% were free of pruritus.

The prophylaxis of different type of cold urticaria also shows good results (**diagram 3**):

Diagram 3. Therapeutic results in 30 patients with cold urticaria – index-duration of remission



after one month prophylaxis 30% have single wheals for a long interval of time after the contact with etiological agent and 5% in shorter intervals. At the end of the second month 80% were without wheals after the expose to cold.

DISCUSSION

The treatment of cold urticaria with Desloratadine is very hopeful. Results show that the clinical features disappeared in most of the patients in the next 2 weeks and in 90% at the end of ford week. This is an excellent effect of treatment in the comparison with the older therapy with the

cyproheptadine, in which case good results were obtained in 50-60 % (18, 24). Desloratadine is powerful, oral antihistamine without sedation, which effectively inhibits the cold reaction, by acting on histamine and leucotrienes (12). It is more effective than cetirizine (6). There are databases that it is more powerful as an inhibitor of leucotrienes than montelukast (7).

Nevertheless the treatment of cold urticaria is long lasting; the risk of adverse reactions is minimal.

We notice that the patients with acquired cold urticaria show faster and with longer duration of treatment than those with hereditary or symptomatic cold urticaria.

CONCLUSION

The received results allow us to make the conclusion that Desloratadine is a good choice in the treatment and prophylaxis of cold urticaria.

REFERENCES:

1. Bonadonna P et al., Treatment of acquired cold urticaria with cetirizine and zafirlucast in combination, *J Am Acad Dermatol*, 2003, 49, 714-6.
2. Doeglas HMG, Ruynten Wj, Schroder FP, Schirm J, Cold urticaria and virus infections: A clinical and serological study in 39 patients, *Br J Dermatol*, 1986, 114, 3, 311-318.
3. Duc J, Pecoud A, Successful treatment of idiopathic cold urticaria with the association of H1 and H2 antagonists: a case report, *Ann Allergy*, 1986, 56, 355-6.
4. Dubertret L, Pecquet C, Murrieta-Aguttes M, Mizolastine in primary acquired cold urticaria, *J Am Acad Dermatol*, 2003, 48, 578-83.
5. Eady RA, Keahey TM, Sibbold R, Kobza Black A, *Clin Exp Dermatol*, 1981, 6, 4, 355-366.
6. Geha RS, Meltzer EO, Desloratadine: a new, nonsedating, oral antihistamine, *J Allergy Clin Immunol*, 2001, 107, 751-62.
7. Genovese A, Pattela V, De Grescenzio G, Loratadine and deethoxycarbonyl-loratadine inhibit the immunological release of mediators from human Fc epsilon RI+ cells, *Clin Exp Allergy*, 1997, 27, 559-67.
8. Hani N, Hartmann K, Casper C, Peters T, Schneider LA, Hunzelmann N, Scharffetter-Kochanek K, Improvement of cold urticaria by treatment with the leucotriene receptor antagonist montelukast, *Acta Derm Venereol*, 2000, 80 (3), 229.
9. Highet AS, Titterton DM, Treatment of urticaria, *Br J Derm*, 1979, 101, 1, 51-55.
10. Hursz S, Toth-Kasa I, Kiss M, Dobozay A, Treatment of cold urticaria, *Int J Dermatol*, 1994, 33, 210-3.
11. Juhlin L, de Vos C, Rihoux JP, Inhibition effect of cetirizine on histamine-induced and 48\ 80- induced wheals and flares, experimental dermatographism, and cold-induced urticaria, *J Allergy Clin Immunol*, 1987, 80, 559-602.
12. Juhlin L, Inhibition of cold urticaria by desloratadine, *J Dermatol Treat*, 2004, 15, 51-54.
13. Maltby NH, Ind PW, Causon RC, Leucotriene E4 release in cold urticaria, *Clin Exp Allergy*, 1989, 19, 33-6.
14. Mazsland AM, Beck MH, Cold urticaria responding to systemic ciclosporin, *Br J Dermatol*, 2003, 149, 214.
15. Mittelbach F, Kalturticaria und Purpura bey Krioglobulinamie, *Z Hautkrankh*, 1987, 62, 6, 481-496.
16. Neittaanmaki H, Fraki JE, Gibson JR, Comparison of new antihistamine acrivastine (BW825C) versus cyproheptadine in the treatment of idiopathic cold urticaria, *Dermatologia*, 1988, 177, 98-103.
17. St-Pierre JP, Kobric M, Rackham A, Effect of ketotifen treatment on cold-induced urticaria, *Ann Allergy*, 1985, 55, 840-3.
18. Razzaque-Ahmed A, Moy R, Acquired cold urticaria, *Int J Dermatol*, 1981, 20, 9, 528-584.
19. Tornick M, Behandlungsergebnisse bei Kalturticaria, Kaltepruritus und Kalterhinist mit Peritol (Zyproheptadin hydrochlorid), *Derm Mschr*, 1979, 165, 4, 274-275.
20. Villas Martinez F, Contreras FJ, Lopez Cazana JM, Lopez Serrano MC, Martinez Alsamora F, A comparison of new nonsedating and classical antihistamines in the treatment of primary acquired cold urticaria, *J Invest Allergy Clin Immunol*, 1992, 2, 258-62.
21. Visitsunthorn N, Tuchida M, Vichyanond H, Cold urticaria in Thai children: comparison between cyproheptadine and ketotifen in the treatment, *Asian Pac J Allergy Immunol*, 1995, 13, 29-35.
22. Wanderer AA, Ellis EF, Treatment of cold urticaria with cyproheptadine, *J Allergy Clin Immunol*, 1971, 48, 366-7.
23. Wanderer AA, St-Pierre JP, Ellis EF, Primary acquired cold urticaria: double-blind comparative study of treatment with cyproheptadine, chlorpheniramine and placebo, *Arch Dermatol*, 1997, 113, 1375-7.
24. Wozel G, Kleine-Natrop HE, Therapie der Kalteurticaria mit Cyproheptadin (Pizotifen), *Dermatol Mschr*, 1981, 167, 1, 30-37.
25. Zuberbier T, Management of urticaria: a consensus report, *J Invest Dermatol Symp Proc*, 2001, 6, 128.
26. Sigler RW, Evan R, Horakova Z, Ottensen E, Kaplan AP, The role of cyproheptadine in the treatment of cold urticaria, *J Allergy Clin Immunol*, 1980, 65, 309-12.